NCT01619293

Brief Summary

Abstract: The most widely studied neuro-markers in traumatic brain injury (TBI) are S100B and neurone specific enolase (NSE). S-100B is localized in astroglia. This marker is used to predict neuronal damage caused by traumatic brain injury. The investigators conduct a study to derive and validate the measurement of S-100B in serum of patients with different types traumatic brain injuries.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,800

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started May 2012

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2012

Completed
29 days until next milestone

First Submitted

Initial submission to the registry

May 30, 2012

Completed
15 days until next milestone

First Posted

Study publicly available on registry

June 14, 2012

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2013

Completed
Last Updated

November 21, 2013

Status Verified

November 1, 2013

Enrollment Period

1.5 years

First QC Date

May 30, 2012

Last Update Submit

November 20, 2013

Conditions

Keywords

CCTbraintraumainjury

Outcome Measures

Primary Outcomes (1)

  • S100B LEVEL

    S-100B level higher than 0.105 ug/L is held pathological

    14 month

Study Arms (6)

Epidural H.

patients with hematoma epidurale

Subdural H.

patients with hematoma subdurale

Subarachnoidal H.

patients with hematoma subarachnoidale

Intracerebral H.

patients with hematoma intracerebrale

E. cerebri

patients with edema cerebri

Concussion

patients with concussion

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients from Level 1 trauma center

You may qualify if:

  • all patients with traumatic brain injury

You may not qualify if:

  • patients without traumatic brain injury

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Medical University of Vienna

Vienna, Vienna, A-1090, Austria

Location

Related Publications (3)

  • Unden J, Bellner J, Astrand R, Romner B. Serum S100B levels in patients with epidural haematomas. Br J Neurosurg. 2005 Feb;19(1):43-5. doi: 10.1080/02688690500089381.

    PMID: 16147582BACKGROUND
  • Biberthaler P, Linsenmeier U, Pfeifer KJ, Kroetz M, Mussack T, Kanz KG, Hoecherl EF, Jonas F, Marzi I, Leucht P, Jochum M, Mutschler W. Serum S-100B concentration provides additional information fot the indication of computed tomography in patients after minor head injury: a prospective multicenter study. Shock. 2006 May;25(5):446-53. doi: 10.1097/01.shk.0000209534.61058.35.

    PMID: 16680008BACKGROUND
  • Mussack T, Kirchhoff C, Buhmann S, Biberthaler P, Ladurner R, Gippner-Steppert C, Mutschler W, Jochum M. Significance of Elecsys S100 immunoassay for real-time assessment of traumatic brain damage in multiple trauma patients. Clin Chem Lab Med. 2006;44(9):1140-5. doi: 10.1515/CCLM.2006.190.

    PMID: 16958611BACKGROUND

Biospecimen

Retention: SAMPLES WITHOUT DNA

7ml of blood drawed from peripheral vein

MeSH Terms

Conditions

Brain Injuries, TraumaticWounds and Injuries

Condition Hierarchy (Ancestors)

Brain InjuriesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesCraniocerebral TraumaTrauma, Nervous System

Study Officials

  • Harald Wolf, M.D.

    Dept. Trauma Surgery; Medical Univ. of Vienna, Austria

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

May 30, 2012

First Posted

June 14, 2012

Study Start

May 1, 2012

Primary Completion

November 1, 2013

Study Completion

November 1, 2013

Last Updated

November 21, 2013

Record last verified: 2013-11

Locations